Stockreport

Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

GENMAB A/S  (GMXAY) 
NASDAQ:AMEX Investor Relations: ir.genmab.com
PDF Company Announcement Type II variation application submitted to the EMA for daratumumab in combination with lenalidomide and dexamethasone as treatment for newly diagno [Read more]